195 related articles for article (PubMed ID: 38539235)
1. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract][Full Text] [Related]
2. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
5.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
6. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
Lin A; Xu W; Luo P; Zhang J
Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
8. TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.
Wu J; Chen W; Zhou Y; Chi Y; Hua X; Wu J; Gu X; Chen S; Zhou Z
Genomics Proteomics Bioinformatics; 2023 Apr; 21(2):259-266. PubMed ID: 36209954
[TBL] [Abstract][Full Text] [Related]
9. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
10. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
11. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
Zhou P; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Wang H
Aging (Albany NY); 2020 Dec; 13(2):2365-2378. PubMed ID: 33318301
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
14. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
Ghorani E; Rosenthal R; McGranahan N; Reading JL; Lynch M; Peggs KS; Swanton C; Quezada SA
Ann Oncol; 2018 Jan; 29(1):271-279. PubMed ID: 29361136
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status.
Mou W; Zhu L; Yang T; Lin A; Lyu Q; Guo L; Liu Z; Cheng Q; Zhang J; Luo P
Cancer Cell Int; 2022 Jul; 22(1):229. PubMed ID: 35836254
[TBL] [Abstract][Full Text] [Related]
16. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
17. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
18. Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma.
Wang C; Xue W; Zhang H; Fu Y
Aging (Albany NY); 2021 Jan; 13(3):4024-4044. PubMed ID: 33428592
[TBL] [Abstract][Full Text] [Related]
19. Spatially aware graph neural networks and cross-level molecular profile prediction in colon cancer histopathology: a retrospective multi-cohort study.
Ding K; Zhou M; Wang H; Zhang S; Metaxas DN
Lancet Digit Health; 2022 Nov; 4(11):e787-e795. PubMed ID: 36307192
[TBL] [Abstract][Full Text] [Related]
20. Identification of microsatellite instability and immune-related prognostic biomarkers in colon adenocarcinoma.
Sun Z; Li G; Shang D; Zhang J; Ai L; Liu M
Front Immunol; 2022; 13():988303. PubMed ID: 36275690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
